dihydroergotamine mesylate

dihydroergotamine mesylate

[dīhī′drō·ərgot′əmēn me′si lāt]
an ergot alkaloid causing vasoconstriction through stimulation of several types of receptors, including alpha-adrenergic receptors and serotonin receptors.
indications It is prescribed for the treatment of migraine and vascular headache.
contraindications Cardiovascular disease, hypertension, liver or kidney dysfunction, sepsis, pregnancy, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse reactions are gangrene and the toxicity of the ergot alkaloids.

Migranal

A nasal spray formulation of an ergot compound used to manage migraines, but not hemiplegic or basilar migraines and not as prophylaxis.
 
Adverse effects
Rarely: cardiac events, including coronary artery vasospasm, transient myocardial ischaemia or infarction, ventricular tachycardia and ventricular fibrillation. More commonly: burning sensation, dysgeusia, diarrhoea, dizziness, drowsiness, dry mouth, hot flushes, irritation, nasal congestion or dryness, nasal discharge, nausea, sinusitis, sore throat, exhaustion, weakness.

dihydroergotamine mesylate

(dī-hī″drō-ĕr-gŏt′ă-mēn)
A vasoconstrictor used in treating migraine.
Mentioned in ?
References in periodicals archive ?
It contains a reformulation of the drug dihydroergotamine mesylate (DHE) in a proprietary Tempo inhaler that allows DHE to be rapidly absorbed from the pleural mucosa into the systemic circulation.
If headaches recur, treat attacks earlier, increase the dose, switch triptans, particularly to naratriptan or frovatriptan, add an NSAID, or switch to dihydroergotamine mesylate, Dr.
The triptans and possibly dihydroergotamine mesylate (DHE-45) can be very helpful for certain types of tension-type headaches, especially in patients who also get migraines.
The Company's lead product candidates during the Class Period were MT-100, a proprietary formulation containing metoclopramide hydrochloride and naproxen sodium, and MT-300, a pre-filled syringe containing dihydroergotamine mesylate, or DHE.
MT 300 is being developed as a new formulation of dihydroergotamine mesylate (DHE) in a prefilled syringe for the acute treatment of migraine.
MT 300 is being developed as an improved and highly purified formulation of dihydroergotamine mesylate (DHE) in a convenient pre-filled syringe that is suitable for at-home use.
MT 300, a proprietary formulation of injectable dihydroergotamine mesylate (DHE) in a pre-filled syringe, is being developed to provide long-lasting pain relief for patients needing a convenient injectable therapy for severe migraine attacks.
MT 300 is being developed as a new, improved product containing dihydroergotamine mesylate (DHE) in a convenient, easy to use pre-filled syringe.